Rates of risk-reducing surgery in Israeli BRCA1 and BRCA2 mutation carriers

Clinical Genetics

Volumn 85, Issue 1, 2014, Pages 68-71

  Laitman, Y ^a   Vaisman, Y ^a   Feldman, D ^b,c   Helpman, L ^b,d,e   Gitly, M ^c   Paluch Shimon, S ^d,e   Berger, R ^d,e   Cohen, L ^c   Narod, S A ^f   Friedman, E ^a,b,e  

^a GERTNER INSTITUTE FOR EPIDEMIOLOGY AND HEALTH POLICY RESEARCH   (Israel)

^b The Meirav Feldshaw Clinic for high risk women   (Israel)

^c Department of Surgery C ^*  (Israel)

^d SHEBA MEDICAL CENTER   (Israel)

^e TEL AVIV UNIVERSITY   (Israel)

^f WOMEN S COLLEGE HOSPITAL   (Canada)

Author keywords

BRCA1 2 mutations; Breast ovarian cancer risk; Jewish Israeli women; Risk reducing surgery

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER PREVENTION; FEMALE; FOLLOW UP; GENE MUTATION; HEALTH CARE UTILIZATION; HETEROZYGOTE; HUMAN; ISRAEL; MAJOR CLINICAL STUDY; MASTECTOMY; MEDICAL HISTORY; OVARY CANCER; PRIORITY JOURNAL; QUESTIONNAIRE; SALPINGOOOPHORECTOMY;

BRCA1/2 MUTATIONS; BREAST/OVARIAN CANCER RISK; JEWISH ISRAELI WOMEN; RISK-REDUCING SURGERY;

ADULT; AGED; FEMALE; GENES, BRCA1; GENES, BRCA2; GENETIC COUNSELING; GENETIC TESTING; GERM-LINE MUTATION; HEREDITARY BREAST AND OVARIAN CANCER SYNDROME; HETEROZYGOTE; HUMANS; ISRAEL; MASTECTOMY; MIDDLE AGED; MUTATION; OVARIECTOMY; PHYSICIAN'S PRACTICE PATTERNS; QUESTIONNAIRES;

EID: 84890203130     PISSN: 00099163     EISSN: 13990004     Source Type: Journal    
DOI: 10.1111/cge.12149     Document Type: Article

References (22)

1. Antoniou A, Pharoah PD, Narod S et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 2003: 72 (5): 1117-1130.
2. Warner E, Plewes DB, Hill KA et al. Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination. JAMA 2004: 292 (11): 1317-1325.
3. http://www.nice.org.uk.
4. Rebbeck TR, Friebel T, Lynch HT et al. Bilateral prophylactic mastectomy reduces breast cancer risks in BRCA1 and BRCA2 mutation carriers. J Clin Oncol 2004: 22: 1055-1062.
5. Rebbeck TR, Lynch HT, Neuhausen SL et al. Reduction in cancer risk after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers. N Engl J Med 2002: 346: 1616-1622.
6. Metcalfe KA, Birenbaum-Carmeli D, Lubinski J et al. International variation in rates of uptake of preventive options in BRCA1 and BRCA2 mutation carriers. Int J Cancer 2008: 122: 2017-2022.
7. Evans DG, Baildam AD, Anderson E et al. Risk reducing mastectomy: outcomes in 10 European centres. J Med Genet 2009: 46: 254-258.
8. Lerman C, Hughes C, Croyle RT et al. Prophylactic surgery decisions and surveillance practices one year following BRCA1/2 testing. Prev Med 2000: 31: 75-80.
9. Evans DG, Lalloo F, Ashcroft L et al. Uptake of risk-reducing surgery in unaffected women at high risk of breast and ovarian cancer is risk, age, and time dependent. Cancer Epidemiol Biomarkers Prev 2009: 18 (8): 2318-2324.
10. Skytte AB, Gerdes AM, Andersen MK et al. Risk-reducing mastectomy and salpingo-oophorectomy in unaffected BRCA mutation carriers: uptake and timing. Clin Genet 2010: 77 (4): 342-349.
11. Laitman Y, Simeonov M, Herskovitz L et al. Recurrent germline mutations in BRCA1 and BRCA2 genes in high risk families in Israel. Breast Cancer Res Treat 2012: 133 (3): 1153-1157.
12. Kram V, Peretz T, Sagi M. Acceptance of preventive surgeries by Israeli women who had undergone BRCA testing. Fam Cancer 2005: 5: 327-335.
13. Wainberg S, Husted J. Utilization of screening and preventive surgery among unaffected carriers of a BRCA1 or BRCA2 gene mutation. Cancer Epidemiol Biomarkers Prev 2004: 13 (12): 1989-1995.
14. Rhiem K, Foth D, Wappenschmidt B et al. Risk-reducing salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers. Arch Gynecol Obstet 2011: 283 (3): 623-627.
15. Singh K, Lester J, Karlan B, Bresee C, Geva T, Gordon O. Impact of family history on choosing risk-reducing surgery among BRCA mutation carriers. Am J Obstet Gynecol 2013: 208 (4): 329.e1-6.
16. Stuckey A, Dizon D, Scalia Wilbur J et al. Clinical characteristics and choices regarding risk-reducing surgery in BRCA mutation carriers. Gynecol Obstet Invest 2010: 69 (4): 270-273.
17. O'Neill SC, Valdimarsdottir HB, Demarco TA et al. BRCA1/2 test results impact risk management attitudes, intentions, and uptake. Breast Cancer Res Treat 2010: 124 (3): 755-764.
18. Beattie MS, Crawford B, Lin F, Vittinghoff E, Ziegler J. Uptake, time course, and predictors of risk-reducing surgeries in BRCA carriers. Genet Test Mol Biomarkers 2009: 13 (1): 51-56.
19. Arver B, Isaksson K, Atterhem H et al. Bilateral prophylactic mastectomy in Swedish women at high risk of breast cancer: a national survey. Ann Surg 2011: 253 (6): 1147-1154.
20. Domchek SM, Friebel TM, Singer CF et al. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA 2010: 304 (9): 967-975.
21. Davison BJ, Breckon E. Factors influencing treatment decision making and information preferences of prostate cancer patients on active surveillance. Patient Educ Couns 2012: 87 (3): 369-374.
22. Yee S, Fuller-Thomson E, Dwyer C, Greenblatt E, Shapiro H. "Just what the doctor ordered": factors associated with oncology patients' decision to bank sperm. Can Urol Assoc J 2012: 6 (5): E174-E178.